简介:目的:研究高效液相色谱法同时测定丸剂1号中芦丁及阿魏酸钠的含量方法。方法:采用YMC-ODS-A(4.6mm×250mm,5μm)色谱柱,柱温25℃,流动相为甲醇-水-36%醋酸(40:60:1.5),流速为1.0mL·min^-1,检测波长为λ1=257nm(芦丁),λ2=322nm(阿魏酸钠)。结果:芦丁、阿魏酸钠进样量分别在0.02—0.26μg(r=0.9998)、0.01~0.27μg(r=0.9998)与各自峰面积呈良好线性关系。二者的平均回收率分别为99.63%(RSD=0.59%),99.77%(RSD=0.98%)。结论:本方法简便、准确、重复性好,可作为丸剂1号的质量控制方法。
简介:Houttuyniacordatapolysaccharide(HCP)isextractedfromHouttuyniacordata,akeytraditionalChinesemedicine.ThestudywastoinvestigatetheeffectsofHCPonintestinalbarrierandmicrobiotainH1N1virusinfectedmice.MicewereinfectedwithH1N1virusandorallyadministratedHCPatadosageof40mg(kg^-1(d^-1.H1N1infectioncausedpulmonaryandintestinalinjuryandgutmicrobiotaimbalance.HCPsignificantlysuppressedtheexpressionofhypoxiainduciblefactor-1αanddecreasedmucosubstancesingobletcells,butrestoredthelevelofzonulaoccludens-1inintestine.HCPalsoreversedthecompositionchangeofintestinalmicrobiotacausedbyH1N1infection,withsignificantlyreducedrelativeabundancesofVibrioandBacillus,thepathogenicbacterialgenera.Furthermore,HCPrebalancedthegutmicrobiotaandrestoredtheintestinalhomeostasistosomedegree.TheinhibitionofinflammationwasassociatedwiththereducedlevelofToll-likereceptorsandinterleukin-1βinintestine,aswellastheincreasedproductionofinterleukin-10.OraladministrationofHCPalleviatedlunginjuryandintestinaldysfunctioncausedbyH1N1infection.HCPmaygainsystemictreatmentbylocalactingonintestineandmicrobiota.Thisstudyprovedthehigh-valueapplicationofHCP.
简介:目的:比较冠心Ⅱ号不同组方对犬急性心肌缺血的保护作用。方法:采用结扎犬冠状动脉前降支的方法造成犬急性实验性心肌缺血模型。描记心外膜电图,计算心肌缺血程度。硝基四氮唑蓝(N-BT)组织化学染色方法测定心肌梗死面积。放射免疫法测定血浆内皮素(ET)和6-酮前列腺素F1α(6-Keto-PGF1α)、血栓烷素(TXB2)活性的变化。同时测定冠脉血流量。结果:冠心Ⅱ号系列组方均具有显著改善犬急性心肌缺血和心肌梗死的作用。在减轻心肌缺血程度方面,各组作用强度基本相当。但微米制剂及汤剂给药组在减小心肌梗死面积、增加冠脉血流量、抑制血浆ET活性、增加血浆6-Keto-PGF1α/TXB2比值方面,较有效组分重组复方、血分药有效组分重组复方、气分药有效组分重组复方作用强,且在作用持续到180分钟时部分作用与血分药、气分药有效组分重组复方组有显著性差异。微米制剂与汤剂作用强度相当。有效组分重组复方疗效优于气分药、血分药重组复方,但无明显差异。结论:冠心Ⅱ号系列组方均有明显对抗犬心肌缺血的作用,但各组药物作用强度有一定差别。
简介:Inthepresentstudy,aseriesofnovelnitricoxide-hydrogensulfidereleasingderivativesof(S)-3-n-butylphthalide((S)-NBP)weredesigned,synthesized,andevaluatedaspotentialantiplateletagents.CompoundNOSH-NBP-5displayedthestrongestactivityininhibitingthearachidonicacid(AA)-andadenosinediphosphate(ADP)-inducedplateletaggregationinvitro,with3.8-and7.0-foldmoreeffectivenessthan(S)-NBP,respectively.Furthermore,NOSH-NBP-5couldreleasemoderatelevelsofNOandH2S,whichwouldbebeneficialinimprovingcardiovascularandcerebralcirculation.Moreover,NOSH-NBP-5couldrelease(S)-NBPwhenincubatedwithratbrainhomogenate.Inconclusion,thesefindingsmayprovidenewinsightsintothedevelopmentofnovelantiplateletagentsforthetreatmentofthrombosis-relatedischemicstroke.
简介:目的:探讨紫癜肾Ⅰ号方含药血清对体外培养大鼠肾小球系膜细胞(rGMC)增殖及活性氧产生的影响。方法:以不同剂量的紫癜肾Ⅰ号方含药血清体外培养大鼠肾小球系膜细胞,采用MTT法检测培养细胞的增殖能力,羟胺法检测培养上清液中超氧化物歧化酶(SOD)水平,比色法检测培养上清液清除活性氧(ROS)能力。结果:紫癜肾Ⅰ号方含药血清能显著抑制体外培养rGMC的增殖,提高培养上清液SOD值水平及清除活性氧单位值,且作用与药物浓度正相关。结论:紫癜肾Ⅰ号方可通过抑制GMC的过度增殖活化、下调ROS生成而减轻紫癜性肾炎(HSPN)的肾小球系膜增生。